Introduction {#s1}
============

The global health agenda has prioritized reduction of maternal mortality for the last two decades. Despite a worldwide decline of 35% from 1990 to 2008,[@pone.0062282-Hogan1] many countries will not meet Millennium Development Goal Five (MDG 5) of reducing maternal mortality by 75% before 2015. [@pone.0062282-United1] The majority of maternal deaths occur in resource-limited settings, despite recent improved access to skilled attendance at delivery, maternity homes in rural areas, emergency obstetric care, mobile clinics, and preconception care.[@pone.0062282-Kidney1],[@pone.0062282-UNICEF1],[@pone.0062282-Atrash1].

Obstetric hemorrhage is the most significant contributor to maternal mortality.[@pone.0062282-Khan1],[@pone.0062282-Ordi1] Delays in identifying hemorrhage, reaching tertiary care facilities, and receiving definitive care such as blood transfusions and surgeries are factors that lead to maternal deaths in limited-resource settings. The non-pneumatic anti-shock garment (NASG) is a low-technology device that offers a potential solution to counteract the effect of these delays. Trials of the NASG in Egypt and Nigeria have demonstrated a 46% decrease in blood loss, 45% decrease in mortality and 81% decrease in severe morbidity in women presenting with obstetric hemorrhage of all etiologies.[@pone.0062282-Miller1].

Implementation of evidence-based maternal mortality interventions is limited by availability of resources and often depends on the strength of the health system.[@pone.0062282-Nyamtema1] Strategies that target women with intrapartum complications that can be managed with basic emergency obstetric care have been shown to be effective in reducing maternal mortality.[@pone.0062282-Campbell1] Interventions that can be used broadly within the health system have the most potential for making a large-scale impact. For example, use of misoprostol for community-based treatment of postpartum hemorrhage (PPH) is considered highly cost-effective, with an incremental cost per disability adjusted life year (DALY) of \$6.[@pone.0062282-Sutherland1].

However, no analysis has examined the cost-effectiveness of the NASG. Application of cost-effectiveness analyses is often limited by use of simulated data. If possible, clinical results are preferred in order to capture unexpected costs.[@pone.0062282-American1] We conducted a cost-effectiveness analysis of the NASG using results from trials in several tertiary facilities in Egypt and Nigeria.

Materials and Methods {#s2}
=====================

Overview {#s2a}
--------

We assessed the cost-effectiveness of adding the NASG to standard hypovolemic shock management. We used clinical data from two published intervention trials, in Egypt and Nigeria, on the effects of the NASG added to standard care on maternal morbidity and mortality at tertiary facilities.[@pone.0062282-Miller1] The analysis focused on a standardized group of 1,000 women presenting in shock, with the proportions of severe (mean arterial pressure \[MAP\] [\<]{.ul}60 mmHg) and mild (MAP\>60 mmHg) shock specified by country to reflect patient characteristics in the clinical trials. We then examined three intervention scenarios: (a) no use of the NASG (i.e., standard care, as the reference case) for any woman in shock; (b) women in severe shock receive the NASG and women in mild shock receive standard care; and (c) all women in shock receive the NASG, regardless of initial shock status. Each scenario was compared incrementally to the reference group (No NASG for any woman in shock). Clinical outcomes (mortality and morbidities) were translated into disability adjusted life years (DALYs), and compared incrementally across scenarios. Costs for the NASG (materials, training, personnel) were collected from project records, and treatments for maternal hemorrhage (e.g., emergency hysterectomy, blood transfusion, and uterotonics) were obtained from local investigators and published sources. All costs were converted into 2010 international dollars. Net cost (or savings) for the NASG was calculated considering the sum of costs for NASG and for clinical management of maternal hemorrhage. Cost-effectiveness was calculated as the cost per DALY averted, which represents the cost for each unit of "disease burden" that the intervention prevents. We conducted a one-way sensitivity analysis. Methods are further described below and in the [Technical appendix S1](#pone.0062282.s001){ref-type="supplementary-material"}.

Clinical data {#s2b}
-------------

We obtained clinical information from two studies that used a two-phase design (pre-intervention (standard care) and NASG intervention plus standard care), conducted in four sites in Nigeria and two sites in Egypt. Funding for these studies came from The John D. and Catherine T. MacArthur Foundation. The pre-intervention phase employed standard care including etiology identification, fluid resuscitation, and uterotonic administration for those with uterine atony.[@pone.0062282-Gulmezoglu1] The intervention phase added the NASG. A total of 1,442 patients with obstetric hemorrhage of any etiology (ranging from ectopic pregnancy to ruptured uterus) were studied. The six participating facilities logged over 100,000 deliveries during the study period, with a severe hemorrhage rate of 1.4%. Women with MAP[\<]{.ul}60 had a significantly greater risk of morbidity and mortality and required additional care.[@pone.0062282-Miller1] Severe morbidity was defined by the Mantel criteria as end-stage organ dysfunction.[@pone.0062282-Mantel1] Additional information is available in the original study manuscripts.[@pone.0062282-Miller1], [@pone.0062282-Miller2], [@pone.0062282-Miller3].

The NASG (Zoex Corporation, Colma, CA) resembles the bottom half of a neoprene wetsuit with an abdominal foam compression ball and Velcro closures that allow perineal and abdominal access; circumferential pressure reduces blood flow to the pelvis and lower extremities and increases cardiac and cerebral perfusion ([Figure 1](#pone-0062282-g001){ref-type="fig"}). During the pre-intervention phase, women with hypovolemic shock secondary to obstetric hemorrhage from any etiology were treated with a standardized shock/hemorrhage protocol.[@pone.0062282-Miller3] Their outcomes were compared to outcomes for similar women treated with the same protocol and the NASG during the intervention phase.

![Image of nurse applying non-pneumatic shock garment (NASG) to study patient in Nigeria^\*^.\
\* Both the provider and patient have given informed consent, as outlined in the PLOS consent form, to publication of their photograph.](pone.0062282.g001){#pone-0062282-g001}

Variables selected for this analysis were in two categories: treatments and outcomes ([Table 1](#pone-0062282-t001){ref-type="table"}). ***Treatment variables*** included mean uterotonic doses, mean units transfused blood, emergency hysterectomies for women with a primary diagnosis of uterine atony and hysterectomies for women with any obstetric hemorrhage etiology. ***Outcome variables*** included mean measured blood loss after drape placement, mean discharge hemoglobin and total number of women with severe anemia or hemoglobin\<7.0 g/dl on discharge (approximated from hematocrit by dividing by a factor of 2.95, rounded to 3, for Nigeria[@pone.0062282-VanSlyke1]), severe morbidity and mortality. We omitted variables that did not differ significantly in the trials by NASG status including other surgeries and procedures.

10.1371/journal.pone.0062282.t001

###### Clinical trial results for women with shock from maternal hemorrhage, by country, shock severity, and use or non-use of the non-pneumatic anti-shock garment (NASG).

![](pone.0062282.t001){#pone-0062282-t001-1}

                                                                                           Egypt         Nigeria                  
  ---------------------------------------------------------------------------------- ------------------ --------- ------- ------- -------
  **1. Number of women in study trials, unstandardized**                                  **All**          432      558     175     277
                                                                                      **Severe Shock**     72       106     109     215
  **2. Mean units of blood transfused per patient** [@pone.0062282-Hogan1]                **All**         2.30     1.61    1.81    1.96
                                                                                      **Severe Shock**    3.30     2.38    2.06    1.96
  **3. Emergency hysterectomy, rate per 1,000** [@pone.0062282-United1]                   **All**         34.01    32.26     0     3.62
                                                                                      **Severe Shock**   180.56    56.60     0     4.65
  **4. Mean units of uterotonics given per patient (all)** [@pone.0062282-Kidney1]        **All**         2.01     1.71    2.59    1.58
                                                                                      **Severe Shock**    2.70     1.65    2.65    1.68
  **5. Proportion of women with discharge Hb\<7.0 g/dl**                                  **All**         4.5%     4.9%    69.1%   61.5%
                                                                                      **Severe Shock**    20.0%    12.2%   80.4%   66.2%
  **6. Severe morbidity,%**                                                               **All**         4.1%     0.9%    2.7%    0.4%
                                                                                      **Severe Shock**    16.7%    3.1%    4.7%    0.0%
  **7. Mortality,%**                                                                      **All**         2.3%     1.1%    16.0%   8.7%
                                                                                      **Severe Shock**    12.5%    5.7%    22.0%   9.3%

[@pone.0062282-Hogan1]. 450 mls per unit [@pone.0062282-United1]. Uterine atony only [@pone.0062282-Kidney1]. Oxytocin and Ergometrine.

Deaths were translated to DALYs using a value of 24 DALYs per death in Egypt and 22 per death in Nigeria. This was based on the difference between median age at maternal death, 28 and 30 and life expectancy at age 70 and 64 for Egypt and Nigeria respectively.[@pone.0062282-1] DALYs per other adverse event ranged from 0.09 for transient severe anemia to 2.5 for infertility secondary to emergency hysterectomy and 9 for long-term motor deficit (which occurred once, in Nigeria). Details on DALYs are provided in the [Technical appendix S1](#pone.0062282.s001){ref-type="supplementary-material"}.

Costs {#s2c}
-----

We included treatment costs in both clinical study phases, as well as program costs in the intervention phase. The following equations were used to calculate costs:

Cost categories included clinical material (disposable and reusable), facility, provider, and laboratory. Unit cost data were collected from local investigators at El Galaa Maternity Hospital in Cairo, Egypt, Assiut University Women's Health Center in Assiut, Egypt, University College Hospital in Ibadan, Nigeria and Katsina General Hospital in Katsina, Nigeria ([Table 2](#pone-0062282-t002){ref-type="table"}). Respondents reported using internal cost accounting systems and hospital charges to patients in order to estimate costs. Due to wide (30-fold) differences in uterotonic unit costs across the Nigerian hospitals, we used a conservative market price.[@pone.0062282-Seligman1] We examined uncertainty in unit costs in the sensitivity analyses.

10.1371/journal.pone.0062282.t002

###### Unit costs by study site, 2010 (Int\$)\[1\].

![](pone.0062282.t002){#pone-0062282-t002-2}

  Costs                                                   Egypt    Nigeria                                                 
  ------------------------------------------------------ -------- --------- -------- ----------------------------- ------- --------
  1\. Hysterectomy[@pone.0062282-United1]                 514.72    51.47    283.09             831.03              75.40   453.21
  2\. 500 ml Blood transfusion                            77.21     51.47    64.34               83.10              32.78   57.94
  3\. 10iu Oxytocin                                        1.12     1.16      1.14    1.11[@pone.0062282-Kidney1]   0.41     0.76
  4\. 0.2 mg Ergometrol                                    1.02     1.02      1.02               4.16               0.27     2.21
  5\. Training cost per patient[@pone.0062282-UNICEF1]     5.27     5.27      5.27               3.57               3.57     3.57
  6\. NASG per use[@pone.0062282-Atrash1]                  7.39     7.38      7.38               7.79               7.79     7.79

[@pone.0062282-Hogan1]. Costs were adjusted from local currency to international dollar with most recently available purchasing power parity (PPP) factors of 2 for Egypt and 78 for Nigeria.^21^ Refer to [Technical appendix S1](#pone.0062282.s001){ref-type="supplementary-material"} for a detailed explanation.

[@pone.0062282-United1]. Differences in hysterectomy cost were investigated and confirmed with local investigators.

[@pone.0062282-Kidney1]. Oxytocin cost from PATH report^28^ for price per dose of \$0.55 USD for an occasional purchase, medium volume.

[@pone.0062282-UNICEF1]. Training costs were standardized across project sites and include provider time during the training.

[@pone.0062282-Atrash1]. Cost includes purchase price of \$295 USD based on 40 uses.

Cost-effectiveness {#s2d}
------------------

We developed a cost-effectiveness model in Microsoft Excel 2004 to calculate net costs and DALYs from adding the NASG to a standard protocol for obstetric hemorrhage and hypovolemic shock. Calculations were performed for 1,000 women experiencing life-threatening obstetric hemorrhage, using standard economic methods, and reflecting the country-specific observed proportions of women in mild and severe shock ([Table 3](#pone-0062282-t003){ref-type="table"}) [@pone.0062282-DrummondM1]. Net costs (or savings) were calculated across intervention scenarios (no NASG for women in shock, NASG for severe shock only, and NASG for all women in shock), for each country ([Table 4](#pone-0062282-t004){ref-type="table"}). Cost-effectiveness was calculated as net cost per DALY averted, or reported as "dominant" for intervention scenarios with lower costs and better health outcomes.

10.1371/journal.pone.0062282.t003

###### Treatments and outcomes for standardized cohorts of 1,000 women with shock from maternal hemorrhage, by NASG intervention scenario\[1\], \[2\].

![](pone.0062282.t003){#pone-0062282-t003-3}

                                                                     Egypt     Nigeria                                
  --------------------------------------------------------------- ----------- --------- --------- --------- --------- ---------
  **1. Projected total blood transfusion for 1,000 women, mls**    1,045,821   971,435   722,024   843,555   812,981   880,606
  **2. Emergency hysterectomies**                                                                                     
  **Emergency hysterectomy-uterine atony dx only, n**                 37         15        32         0         3         3
  **All emergency hysterectomies**                                    95         68        54         0        17        21
  **3. Uterotonic (any)**                                                                                             
  **Oxytocin, total 10iu doses**                                     1,433      1,303     1,226     2,401     1,793     1,499
  **Ergometrine, total.2 mg doses**                                   578        520       488       191       99        80
  **4. Total number of women with discharge Hb\<7.0 g/dl**            59         45        53        739       637       626
  **5. Severe morbidity, n**                                          48         24         9        34         0         5
  **6. Mortality, n**                                                 25         12        10        175       84        85

[@pone.0062282-Hogan1]. Proportion of cohort with severe shock (MAP\<60) is 18% for Egypt and 72% for Nigeria. This is derived from clinical trial data^15,16^, combining pre and post trial periods.

[@pone.0062282-United1]. Top 3 definitive diagnoses by country and study phase: Egypt: \[Pre (N = 432): Uterine atony (34%), Ectopic pregnancy (19%), Placental abruption (14%)\] \[Post (N = 558): Uterine atony (44%), Abortion complications (14%), Ectopic pregnancy (13%)\] Nigeria \[Pre (N = 175): Retained placenta (30%), Uterine atony (25%), Placental abruption (11%)\] \[Post (N = 277): (Uterine atony (26%), Retained placenta (23%), Placental abruption (17%)\].

10.1371/journal.pone.0062282.t004

###### Calculated mortality, morbidity, disability-adjusted life years, cost, and cost-effectiveness for 1,000 women with severe or mild shock\[1\] from maternal hemorrhage, by intervention scenario.
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                          Intervention scenario             Mortality   Morbidity   Total DALYs     Cost     ICER (\$ per DALY averted)[@pone.0062282-Kidney1]                                          
  ------------- ------------------------------------------ ----------- ----------- ------------- ---------- --------------------------------------------------- ------- --------- --------- ----------- ----------
  **Egypt**                                                                                                                                                                                             
                               **No NASG**                    24.7                      48                                          730                                  147,248                        
                        **NASG only if MAP \< 60**            12.4       −49.79%        24        −50.59%                           372                          −357    137,760   −9,489    Dominant   
                 **NASG for all** [@pone.0062282-UNICEF1]     10.2       −17.93%         9        −159.39%                          335                           −37    116,507   −21,253   Dominant    Dominant
  **Nigeria**                                                                                                                                                                                           
                               **No NASG**                    175.0                     34                                         3960                                  100,003                        
                        **NASG only if MAP \< 60**            83.8       −52.09%         0        −100.00%                         1896                          −2063   106,463    6,460     \$3.13    
                 **NASG for all** [@pone.0062282-UNICEF1]     85.2        1.68%          5          N/A                            1923                           27     116,240    9,777    Dominated    \$7.97

1\. Proportion of cohort with severe shock (MAP\<60) is 18% for Egypt^16^ and 72%^15^ for Nigeria (from clinical trial, combining pre and post trial periods).

2.\"Difference\" is versus prior row (scenario). Negative values in \"difference\" columns are desirable --- disease burden or cost averted.

3\. \"Dominant\" means cheaper and better health outcomes than previous intervention scenario. \"Dominated\" means more costly and worse outcomes than previous scenario.

4\. Results for \"NASG only if MAP \<60\" are more stable than for the incremental effect of \"NASG for all\", due to the small number of clinical events for mild shock group in original trials; see text.

Training costs to treat 1,000 women were annualized assuming that training effects would last 10 years. Training components (venues, trainee per diems, and trainer salaries) and prices were estimated based on the experience in the Nigerian and Egyptian studies.

Intractable uterine atony is the only hemorrhage etiology for which emergency hysterectomy can be directly reduced by the NASG, because pelvic vascular compression can control blood loss until uterine contraction occurs. However, women who present with shock secondary to other obstetric hemorrhage etiologies (e.g., abruption placenta, ruptured uterus) and are stabilized with the NASG may then survive long enough to have the chance to receive the needed hysterectomy. For this reason, costs were examined in two ways: for hysterectomies secondary to primary uterine atony and for hysterectomies of all etiologies. Results were similar for both approaches, so we present results using the narrower scope and can provide the broader analysis on request.

All costs were converted from Egyptian Pounds and Nigerian Naira to 2010 international dollars using the most recently available conversation factors.[@pone.0062282-2]

We conducted sensitivity analyses to take into account possible variation in our baseline values. A one-way sensitivity analysis adjusted input parameters by 50% above or below the base case or used published ranges if available from prior NASG trials[@pone.0062282-Miller1], [@pone.0062282-Krahn1] ([Table 5](#pone-0062282-t005){ref-type="table"} and [Technical appendix S1](#pone.0062282.s001){ref-type="supplementary-material"}). We also examined different approaches to assigning unit costs in Nigeria due to the very different costs between Northern and Southern Nigeria.

10.1371/journal.pone.0062282.t005

###### One-way sensitivity analysis on cost and health differences between two intervention scenarios: NASG for severe shock and No NASG.

![](pone.0062282.t005){#pone-0062282-t005-5}

                                                   Egypt                       Nigeria                                                                                                                   
  --------------------------------------------- ------------ ------------------------------------------- ----------------- ------------------------------------------- --------------------------------- ----------------
  **Costs**                                                       Net \$ per 1000 women with shock                              Net \$ per 1000 women with shock                                         
  Base case result                                                                                           −\$9,489                                                                                        \$6,460
  1\. NASG (per use)                              *\$7.38*        1.36[@pone.0062282-Hogan1], 11.06       −10,572, −8,828                   *\$7.79*                    3.9[@pone.0062282-Hogan1], 11.7    3,671, 9,262
  2\. Uterotonics                                 *\$1.14*                   0.57, 1.71                   −9,388, −9,603                    *\$0.76*                              0.38, 1.14               6,327, 6,858
  3\. Blood transfusion                          *\$64.34*                  32.17, 96.51                  −4,703, −14,275                    *\$58*                                 29, 87                 8,231, 4,688
  4\. Emerg. Hyst                                *\$283.09*                141.55, 424.64                 −6,334, −12,643                    *\$453*                               227, 680                5,704, 7,215
  **Health**                                                  Change in DALYs per 1000 women with shock                     Change in DALYs per 1000 women with shock                                    
  Base case result                                                              −357                                                         −2,063                                                      
  1\. Mortality effect[@pone.0062282-United1]      *1.00*                     0.80, 1.2                     −406, −309                       *1.00*                                0.80, 1.2              −2,354, −1,772
  2\. Morbidity effect                             *1.00*                     0.80, 1.2                     −364, −351                       *1.00*                                0.80, 1.2              −2,074, −2,053
  *3.* Severe anemia effect                        *1.00*                     0.50, 1.5                     −358, −356                       *1.00*                                0.50, 1.5              −2,085, −2,041
  4\. Infertility                                  *1.00*                     0.50, 1.5                     −371, −344                       *1.00*                                0.50, 1.5              −2,068, −2059

[@pone.0062282-Hogan1]. Price based on cost provided by Blue Fuzion based in Hong Kong.

[@pone.0062282-United1]. Health effect indicates risk of event compared with the base case, i.e., effect  =  0.80 means 20% lower risk of mortality or morbidity for the \"NASG for severe shock\" scenario than assumed in the main analysis.

Results {#s3}
=======

Clinical outcomes {#s3a}
-----------------

The published trial data, adjusted to standard cohorts of 1,000 women, are displayed in [Table 3](#pone-0062282-t003){ref-type="table"} by country and intervention scenario; no NASG for women in shock, NASG for women in severe shock only, and NASG for all women in shock. The clinical effect of the NASG was most significant for women presenting with severe shock. Use of the NASG in this group reduced overall cohort mortality by 52% in both groups (13--91 per 1000 women in shock), and severe morbidities by 50--100% (24--34 per 1000 women in shock). Units of blood transfused decreased by 7% in Egypt and 4% in Nigeria. The number of units of uterotonics administered was roughly 9% lower in Egypt and 25% lower inNigeria.

When all women received the NASG in Egypt, there were directionally similar but much smaller magnitude and statistically non-significant benefits. In Nigeria, blood transfusions increased by 8.3%, and there were small and statistically non-significant increases in mortality and severe morbidity.

In Egypt, the number of hysterectomies among women with uterine atony was 59% lower if women in severe shock receive the NASG. In Nigeria, there were very few hysterectomies performed; all were in the NASG phase and most were not associated with uterine atony. The reported number of women in severe shock with severe anemia (Hb\<7.0) on discharge was lower for women using the NASG, in both Egypt and Nigeria.

These clinical findings translate into 357 DALYs averted by NASG use for women in severe shock in Egypt and 2063 in Nigeria ([Table 4](#pone-0062282-t004){ref-type="table"}). Reduced mortality accounts for most (82--96%) of the DALYs averted in this cohort (not in table). If women in mild shock also received the NASG, the estimates of incremental changes in DALYs (+27 to --37) are much smaller and unstable due to few clinical events and thus statistical uncertainty in the original studies among women in mild shock.

Costs {#s3b}
-----

The categories of cost include emergency hysterectomies, blood transfusions, uterotonics, and provider training for use of the NASG, and the NASG itself.

In Egypt, per 1,000 women, providing the NASG to women in severe shock resulted in net savings of Intl\$ 9,489. Major savings were derived from reduced blood transfusions (\$9,572). The primary added cost in this group was for the NASG and associated training. In Nigeria, using the NASG for severe shock resulted in incremental net costs of Intl \$6,460. The NASG saved \$3,543in blood transfusions. However, the savings were more than offset by higher costs of more hysterectomies, as well as the costs of the NASG and training. Providing the NASG for all women in shock resulted in further savings in Egypt and further costs in Nigeria, though again with uncertainty due to precision issues.

Cost-effectiveness {#s3c}
------------------

Providing the NASG to women in severe shock is cost-saving for Egypt and cost-effective for Nigeria. Cost-effectiveness ratios for women experiencing shock from maternal hemorrhage are summarized in the final columns of [Table 4](#pone-0062282-t004){ref-type="table"}.

In Egypt, providing the NASG for women presenting with severe shock was "dominant," saving \$9,489 and averting 357 DALYs per 1,000 women. (No cost-effectiveness ratio is needed with lower costs and better outcomes.) The benefits for treating all women with the NASG were lower (37 averted DALYs with \$21,253 in incremental savings), and uncertain due to unstable estimates of clinical outcomes and thus DALYs, as noted above.

In Nigeria, with only women with severe shock receiving the NASG, the NASG had a net cost of \$6,460 and averted 2,063 DALYs, for an incremental cost-effectiveness ratio (ICER) of Intl\$ 3.13 per DALY averted. Unfavorable incremental results occur when women in mild shock also received the NASG: \$9,777 in increased costs and 27 additional DALYs. As with the small gains in Egypt, these results are uncertain due to unstable estimates of clinical outcomes and thus DALYs.

In settings where the intermediate intervention scenario (NASG only for women in severe shock) is considered infeasible, it is appropriate to compare the more extreme scenarios. In Egypt, "NASG for all" option dominates "No NASG". In Nigeria, this comparison has a cost-effectiveness ratio of \$4.13 per DALY averted.

Sensitivity analyses {#s3d}
--------------------

One-way cost-effectiveness analyses for the uterine atony-only hysterectomy scenario with women in severe shock only receiving the NASG are presented in [Table 5](#pone-0062282-t005){ref-type="table"}. Per standard protocol, costs were varied +/-- 50% unless market cost ranges were available (i.e. NASG \$1.36--11.06 in Egypt; \$3.90--11.70 in Nigeria; single use). As the cost of blood transfusion increases, the NASG becomes more cost saving in Egypt. Varying the cost of blood by +/-- 50%, we found overall cost savings in Egypt ranged from \$4,703--14,275, while in Nigeria the net cost ranged from \$4,688--8,231. Even when the number of units of blood was removed from the equation, the NASG remained cost saving and cost-effective in Egypt and Nigeria, respectively. Removing uterotonics from the equation had a minor effect on the cost-effectiveness.

Although the clinical trials used garments purchased at \$170 USD, the current (higher) market value of \$295 was used in this analysis. When we increased the cost of the NASG at baseline by 50% to \$11.06 (\$11.70 in Nigeria)[per use]{.ul}in the severe shock group, the cost savings in Egypt fell by roughly 7%. When we set the price of the NASG at the lowest available market cost \[SM1\] of \$53.76 plus cleaning, or \$1.36 per use in Egypt and \$3.90 in Nigeria, savings in Egypt increased by 10% and costs in Nigeria decreased by 43%.

The DALYs health effect estimates for women in severe shock receiving the NASG (+/-- 20% for morbidity and mortality; +/-- 50% for severe anemia and infertility) are most sensitive to mortality parameters. As the NASG increases its efficacy in saving lives, more DALYs are averted. For example, when the NASG is 20% more effective at mortality reduction, women in severe shock gain an additional 49 DALYs in Egypt and 291 DALYs in Nigeria. Altering the effect of severe morbidity, severe anemia and infertility have less significant impact on total DALYs.

Discussion {#s4}
==========

For women in severe shock, the NASG intervention, even with conservative assumptions (highest price), is an economically attractive option for health systems aiming to reduce maternal mortality from hemorrhage and shock. It is cost-saving in Egypt, when compared to standard care only. In Nigeria, it is highly cost-effective, \$3 per DALY averted, far below the WHO standard for "very cost-effective" defined as the annual gross domestic product (GDP) per capita.[@pone.0062282-Acharya1] In comparison, a highly favorable maternal mortality intervention in urban India focused on improved intrapartum care had costs of \$150--350 per DALY averted.[@pone.0062282-Goldie1]

Importantly, the NASG provides a very high health benefit for women in severe shock. For each woman in severe shock receiving the garment, the average expected benefit is 2.0 -- 2.9 DALYs averted, i.e., between 2 and 3 added years of life. Few interventions provide this magnitude of health gain. The results with mild shock are of far lower magnitude, and uncertain in direction due to small numbers of events (especially deaths) and thus statistical uncertainty in the clinical trials.

The financial benefit of the NASG is that it allows providers to use fewer medical care resources. In some low-income settings, safe units of blood are scarce and often sold on the black market for high prices. In Nigeria, like other developing countries, patients may die because of deficiencies in blood banking or lack of supply.[@pone.0062282-OsobuAsubiojo1] The cost of blood in our analysis is roughly 60 international dollars per unit. In Egypt, patients with the NASG use, on average, 0.8 fewer units of blood than those without. In Nigeria, blood supply is highly variable: from the authors' clinical experience, patients often receive blood only if a family member donates it, and thus its use may be more contingent on availability than clinical need. Yet the average number of units of blood was slightly lower with the NASG for women in severe shock.

Likewise, women in severe shock who were put in the NASG used an average of one fewer dose of an uterotonic, in both Egypt and Nigeria. While the cost of a dose of uterotonics is significantly less than a unit of blood, each provide an example of how the use of the NASG can conserve resources. Additional research is needed to determine the contexts within and to the degree to which the NASG is effective in reducing use of blood, uterotonics, and number of surgeries.

In this analysis, emergency hysterectomies served as an indicator for the severity of a woman's hemorrhage; if the hemorrhage was uncontrolled, or appeared uncontrollable, by medical or more conservative surgeries, a hysterectomy might be performed as an extreme effort to save the woman's life. In previous trials,[@pone.0062282-Miller2], [@pone.0062282-Miller3] the efficacy of the NASG was most definitive for women with a diagnosis of uterine atony. Often for women with other diagnoses, such as placental abruption, an emergency hysterectomy still may be required despite the efficacy of the NASG in controlling bleeding; indeed, the NASG may stabilize women enough to permit life-saving hysterectomies. For women in severe shock, hysterectomies decreased with the NASG for both uterine atony and all etiologies in Egypt, thus saving resources. In Nigeria, the rate of hysterectomies overall was very low (2%), and in the trial only one hysterectomy was performed for a woman with uterine atony who received the NASG. Hysterectomies for other etiologies rose with NASG. Additional studies are needed to determine the efficacy of the NASG in conserving surgical resources across various settings, and if the increase in surgeries was due to the increased chance of a woman surviving long enough to receive the surgery if she had the NASG compared to those who did not.

If the savings due to the averted use of medical resources is excluded, the "crude" ICER for the NASG material costs and training is Intl\$ 6.37 in Egypt and 3.95 in Nigeria (for the analysis including hysterectomies for uterine atony only). This means that use of the NASG appears very cost-effective even in a clinical setting where blood, uterotonics, and surgery are unavailable. Additional studies are needed to determine the cost-effectiveness of the NASG in a variety of clinical settings to set priorities for implementation.

This analysis was stratified by shock level because resource allocation and protocol for shock management is often dependent on severity of shock. The NASG is very favorable for women with severe shock, but has far smaller and, in this study, inconsistent results for those with mild shock. In Egypt, there was only one death in the entire study (N = 619) for those in mild shock. As mortality accounts for a majority of DALYs averted in the severe shock phase, the mild shock results are markedly different, with a high proportion of DALYs contributed by the infertility associated with hysterectomies.

In Nigeria, the number of women in the trial's mild shock group (N = 127 total pre- and with NASG) was markedly smaller than for the other groups. Nigerian women in these studies had less access to care compared to women in the Egyptian study sites, and were more likely to come to the facility already bleeding and in severe shock. Thus, the standardized cohort size of 1000 exaggerated the number of key clinical events. There were 4 deaths out of 66 without the NASG, and 4 deaths out of 61 with the NASG, suggesting a statistically insignificantly higher mortality in the NASG group. Also, there was only one hysterectomy. Therefore, DALY calculations are highly uncertain. The number of units of blood and doses of uterotonics also increased, for unclear reasons. Perhaps these changes were due to temporal changes associated with better adherence to protocol, or may reflect changes due to availability of resources. More research is needed to determine the cost-effectiveness of the NASG for women presenting in mild shock.

NASG use resulted in reductions in severe morbidity, ranging from 81--100% for women presenting with severe shock. Cost estimates are conservative and exclude cost offsets from a decline in anemia. The NASG reduced the number of women with severe anemia (by 39% in Egypt and 18% in Nigeria). Although we could not measure the effect of anemia on the study participants' postpartum productivity, anemia has been associated with decreased postpartum economic productivity (Galloway 2003[@pone.0062282-Galloway1]).

The range of trial results by site and country indicate that the NASG will have varied effects on clinical practice, morbidity, and mortality, dependent on pre-existing resources and patient condition on arrival. A large-scale, randomized cluster trial currently being conducted in Zambia and Zimbabwe may shed more light on the effect of the NASG in the context of different health systems.

A limitation of this analysis is the variability in cost collection methods from local investigators. Some sites were only able to report hospital fees for emergency hysterectomy because they had no access to complete cost data. The collected costs were compared to costs detailed in the CHOICE series,[@pone.0062282-Acharya1] which were lower than costs at UCH and El Galaa and similar to the other two sites. A sensitivity analysis was performed in order to more accurately represent health system costs.

Scaling up the NASG by distributing a larger number to each health system region may provide opportunities for greater efficiency. An identical NASG prototype has been developed and tested for \$53.76 per garment as opposed to the current price of \$295[@pone.0062282-World1] per garment, and can be purchased in a minimum order of 1,000 garments (Blue Fuzion, Hong Kong[@pone.0062282-PATH1]). Additional manufacturers are being added in Asia. The NGO organization PATH has recommended establishment of regional distributors, and of exclusive garment rights, if necessary to protect from excessively high prices.[@pone.0062282-PATH1] Additionally, if training on the NASG were included in the standard emergency obstetric care curriculum for medical, midwifery and nursing students, programmatic training costs would be reduced.

We found that the NASG is cost saving or highly cost-effective for women in severe hypovolemic shock when administered in a tertiary care setting. It may become even less costly to implement if sales prices continue to decrease, and it becomes part of pre-service training. Future research is needed to validate the cost-effectiveness and efficacy of the NASG in other settings. The Zambia and Zimbabwe trial noted above compares effect on outcomes of earlier application of the NASG at the community level before transport to tertiary facilities. Once those results are published, we will conduct a CEA of NASG use to determine level of care at which the NASG will be most cost-effective.
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